Linked Data API

Show Search Form

Search Results

386888
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL997 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL995 more like this
HL996 more like this
star this property question first answered
less than 2015-07-14T15:34:29.553Zmore like thismore than 2015-07-14T15:34:29.553Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
unstar this property title 2013-14 Annual Report more like this
unstar this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386887
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL996 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL995 more like this
HL997 more like this
star this property question first answered
less than 2015-07-14T15:34:29.297Zmore like thismore than 2015-07-14T15:34:29.297Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
unstar this property title 2013-14 Annual Report more like this
unstar this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386884
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what progress has been made on setting up a study to image amyloid deposition in systemic amyloidosis using hybrid positron emission tomography-magnetic resonance imaging; where the study is located; how many patients have been recruited; when the study is expected to complete its initial work; and where the results will be published. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL993 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>This is a single centre study at University College London Hospital. It has now been set up and one patient has been recruited and scanned. The current planned date for end of recruitment is 1 October 2016. It is anticipated that the data will be analysed and submitted for publication in a peer reviewed journal within a year of the end of recruitment.</p><p> </p> more like this
star this property answering member printed Lord Prior of Brampton more like this
star this property question first answered
less than 2015-07-14T15:36:20.96Zmore like thismore than 2015-07-14T15:36:20.96Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
unstar this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
421282
star this property registered interest false more like this
star this property date less than 2015-10-14more like thismore than 2015-10-14
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government, following the successful Phase 1 trials combining CPHPC and the antibody –SAP for the treatment of Amyloidosis, when they expect Phase 2 trials to commence, and what resource the National Institute for Health Research is making available to University College London to support this work. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL2653 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-10-22more like thismore than 2015-10-22
star this property answer text <p>Results in the first 15 patients with systemic amyloidosis treated with a combination of CPHPC and anti-SAP antibody have been published in the <em>New England Journal of Medicine</em>. The phase I study is funded by GlaxoSmithKline (GSK) and the research team includes researchers at University College London (UCL) and the National Amyloidosis Centre (NAC).</p><br /><p>The National Institute for Health Research Clinical Research Network (CRN) provides support to help the life sciences industry delivery high quality commercial contract clinical research in the national health service. If a phase II trial is developed, the CRN will work with GSK, the NAC and UCL as appropriate, to deliver the trial.</p> more like this
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN HL2652 more like this
star this property question first answered
less than 2015-10-22T12:13:17.993Zmore like thismore than 2015-10-22T12:13:17.993Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
unstar this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
421281
star this property registered interest false more like this
star this property date less than 2015-10-14more like thismore than 2015-10-14
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis remove filter
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what progress is being made by University College London in association with the National Amyloidosis Centre and GlaxoSmithKline to develop a combined small molecule antibody treatment for amyloidosis. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL2652 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-10-22more like thismore than 2015-10-22
star this property answer text <p>Results in the first 15 patients with systemic amyloidosis treated with a combination of CPHPC and anti-SAP antibody have been published in the <em>New England Journal of Medicine</em>. The phase I study is funded by GlaxoSmithKline (GSK) and the research team includes researchers at University College London (UCL) and the National Amyloidosis Centre (NAC).</p><br /><p>The National Institute for Health Research Clinical Research Network (CRN) provides support to help the life sciences industry delivery high quality commercial contract clinical research in the national health service. If a phase II trial is developed, the CRN will work with GSK, the NAC and UCL as appropriate, to deliver the trial.</p> more like this
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN HL2653 more like this
star this property question first answered
less than 2015-10-22T12:13:17.917Zmore like thismore than 2015-10-22T12:13:17.917Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
unstar this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
722130
star this property registered interest false more like this
star this property date less than 2017-04-18more like thismore than 2017-04-18
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, how many people have been diagnosed with amyloidosis in each of the last five years. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 71136 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-04-26more like thismore than 2017-04-26
star this property answer text <p>The Department does not hold data on the number of patients diagnosed with amyloidosis.</p><p> </p><p>The National Amyloidosis Centre at University College Hospital, London estimates that there are around 600 new cases of the condition each year.</p> more like this
star this property answering member constituency Oxford West and Abingdon more like this
star this property answering member printed Nicola Blackwood more like this
star this property question first answered
less than 2017-04-26T09:25:38.84Zmore like thismore than 2017-04-26T09:25:38.84Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
unstar this property tabling member
4131
unstar this property label Biography information for Jim Shannon more like this